Seres Therapeutics (MCRB) Amortizatization of Intangibles (2016 - 2023)
Seres Therapeutics (MCRB) posted Amortizatization of Intangibles of $49000.0 for Q2 2023, down 73.8% sequentially from $187000.0 in Q1 2023, and up 120.94% YoY from $22177.9 in Q2 2022.
Seres Therapeutics (MCRB) Amortizatization of Intangibles (2016 - 2023) Analysis & Trends
Seres Therapeutics has reported Amortizatization of Intangibles for 8 years, with the latest figure at $49000.0 in Q2 2023.
- Quarterly Amortizatization of Intangibles rose 120.94% year-over-year to $49000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $49000.0 (up 126.06% YoY) and the FY2023 annual result came in at $236000.0, up 134.3% from the prior year.
- Amortizatization of Intangibles declined to $49000.0 in Q2 2023 per MCRB's latest filing, from $187000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.6 million in Q4 2021 and troughed at -$851000.0 in Q1 2021.
- A 5-year average of -$87400.0 and a median of -$12000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2019 and 2021: Amortizatization of Intangibles jumped 466.67% in 2019, then slumped 17300.0% in 2021.
- Over 5 years, Amortizatization of Intangibles stood at $85000.0 in 2019, then plunged by 748.24% to -$551000.0 in 2020, then surged by 390.2% to $1.6 million in 2021, then tumbled by 100.75% to -$12000.0 in 2022, then jumped by 508.33% to $49000.0 in 2023.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $49000.0, $187000.0, and -$12000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 49,000.00 |
| Mar 31, 2023 | 187,000.00 |
| Mar 31, 2023 | 187,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Sep 30, 2022 | -129,000.00 |
| Sep 30, 2022 | -129,000.00 |
| Jun 30, 2022 | -234,000.00 |
| Jun 30, 2022 | -234,000.00 |
| Mar 31, 2022 | -313,000.00 |
| Mar 31, 2022 | -313,000.00 |
| Dec 31, 2021 | 1.60 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | -516,000.00 |
| Sep 30, 2021 | -516,000.00 |
| Jun 30, 2021 | -730,000.00 |
| Jun 30, 2021 | -730,000.00 |
| Mar 31, 2021 | -851,000.00 |
| Mar 31, 2021 | -851,000.00 |